News Agency
The Times

HanAll Biopharma Signs Licensing Agreement with Turn Biotechnologies to Develop Novel Treatments for Eye and Ear Diseases

  • Written by PR Newswire
HanAll Biopharma Signs Licensing Agreement with Turn Biotechnologies to Develop Novel Treatments for Eye and Ear Diseases
  • Exclusive agreement allows HanAll to utilize Epigenetic Reprogramming of Aging (ERATM) technology for ophthalmic and otic diseases.
  • Collaboration aims to leverage HanAll's extensive expertise in ophthalmic and otic diseases and Turn Bio's cellular reprogramming technology to create innovative therapies.
  • Deal value can exceed $300 million USD for the...

Read more: HanAll Biopharma Signs Licensing Agreement with Turn Biotechnologies to Develop Novel Treatments...

How Can Businesses Reduce the Risk of Commercial Litigation?

Commercial disputes often begin with a misunderstanding, an unclear contract or a delayed response to a growing problem. Seeking early advice from Litigation Lawyers Sydney with PCL lawyers can help businesses trust and identify legal risks, clarify obligations and create a strategy... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion